Kronos Bio Announces Participation in Upcoming Investor Conferences
01 Giugno 2023 - 10:05PM
Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to
transforming the lives of those affected by cancer, today announced
that members of the management team will participate in fireside
chats at the following investor conferences:
- Jefferies
Healthcare Conference on Thursday, June 8, 2023, at 8:30 a.m. ET;
and
- Goldman Sachs
44th Annual Global Healthcare Conference on Thursday, June 15,
2023, at 10:40 a.m. PT.
The fireside chats will be available on
the Investors & Media section of the company’s
website at www.kronosbio.com. A replay of the webcasts will be
archived and available for one month following each event.
About Kronos Bio, Inc.Kronos Bio is a
biopharmaceutical company that is advancing two investigational
compounds in clinical trials for patients with cancer. The company
is developing the CDK9 inhibitor KB-0742 as a treatment for
MYC-amplified solid tumors and other transcriptionally addicted
solid tumors and lanraplenib, a next-generation SYK inhibitor, for
patients with FLT3-mutated acute myeloid leukemia. The company’s
scientific focus is on developing medicines that target the
deregulated transcription that is the hallmark of cancer and other
serious diseases.
Kronos Bio is based in San Mateo, Calif., and has a research
facility in Cambridge, Mass. For more information, visit
www.kronosbio.com or follow the company on LinkedIn.
Company Contact:Sarah Connors, Vice President
of Investor Relations and Corporate CommunicationsKronos
Bio857-290-7305sconnors@kronosbio.com
Investors:Leo VartorellaArgot
Partners212-600-1902kronosbio@argotpartners.com
Media:Georgia West/David RosenArgot
Partners212-600-1494kronosbio@argotpartners.com
Grafico Azioni Kronos Bio (NASDAQ:KRON)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Kronos Bio (NASDAQ:KRON)
Storico
Da Giu 2023 a Giu 2024